$BWXT

BWX (NYSE:BWXT) misses Q3 2026 sales expectations

BWX reported Q3 2026 revenue of $953M, missing estimates by 2.1% but beating EPS expectations. Adjusted EBITDA and free cash flow margins improved. Management maintained full-year EPS guidance at $4.74 and raised EBITDA guidance. Backlog grew 15.6% year-on-year to $8.56B.

Original reporting
Published Nov 2, 2026, 9:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 9:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
BWX (NYSE:BWXT) misses Q3 2026 sales expectations — source image
Decision brief

The 30-second read

$BWXTNeutralMed
01

Why it matters

Traders will likely focus on the split between top-line underperformance and bottom-line strength, then weigh it against reiterated full-year adjusted EPS guidance and higher EBITDA guidance.

02

Market read

A revenue miss with EPS/EBITDA beats and supportive backlog and cash-flow margin changes creates a mixed but tradable setup for near-term positioning.

03

What to watch

Backlog rose to $8.56B (+15.6% YoY) and free cash flow margin improved to 15.8%, which may outweigh the single-quarter revenue shortfall for forward order conversion.

Relevance 7/10Novelty 7/10Timing: after-hours/next-session positioning following the Q3 2026 results and guidance reiteration

Background

The article summarizes BWX Technologies’ Q3 2026 results versus S&P analysts’ consensus and reiterates full-year guidance.

Company-level read

Ticker impact

$BWXTNeutralMedium confidence
Context

BWX Technologies reported Q3 2026 revenue of $953M, missing analysts’ $973.1M consensus, while adjusted EPS beat at $1.26 vs $1.19.

Expected impact

Likely choppy trading, with downside risk from the revenue miss offset by support from EPS/EBITDA outperformance and steady-to-up guidance.

Evidence & confidence

The article’s key decision inputs are a revenue miss versus consensus, adjusted EPS and EBITDA beats, and reiterated full-year adjusted EPS guidance with EBITDA guidance above consensus.

Market effects

Nuclear/defense industrials read-through may hinge on whether revenue softness is company-specific or signals broader demand timing.

Limited, primarily affects US defense/nuclear supply-chain sentiment rather than a broad regional macro move.

Low, as the disclosure is company-specific and not tied to global policy or supply shocks.

Counterpoint

The revenue miss could be timing-related while profitability and backlog growth remain strong, making the quarter less bearish than the headline implies.

Key entities

  • BWX Technologies

    Reported Q3 2026 revenue, adjusted EPS, EBITDA, free cash flow margin, backlog, and reiterated full-year guidance.

Related articles

$BWXTMedAI 8/10

BWXT Q3 2026 Earnings Call Transcript

BWXT reported Q3 2026 revenue of $953M, up 10% YoY, with Adjusted EBITDA at $180M and EPS at $1.26. Government Operations saw 22.6% EBITDA margin, while Commercial Operations grew 25%. The company secured contracts for nuclear projects, including the U.S. Army's Janus Program and a Canadian microreactor project. BWXT raised its 2026 free cash flow guidance to $350M-$360M and plans capacity expansions.

$BWXTMedAI 8/10

BWX Technologies Q3 Earnings Call Highlights

BWX Technologies reported Q3 highlights, including a $189M fuel contract and revenue growth in special materials. The company is advancing nuclear projects, such as a high-enriched uranium facility and a large-scale HPDU plant. BWXT also secured awards for its advanced nuclear reactors and raised its 2026 free-cash-flow outlook to $350M-$360M, maintaining adjusted EBITDA and EPS guidance.